PET/CT staging of Hodgkin lymphoma in no need of routine BMB

11/14/2012 | DoctorsLounge.com

Routine bone marrow biopsy did not have a significant effect on treatment management in patients with treatment-naive Hodgkin lymphoma staged with 18F-FDG-PET/CT, according to a study in the Journal of Clinical Oncology. "The added diagnostic value from routine BMB was minimal, and positive BMB findings implied upstaging in only five patients from stage III to stage IV disease of a total of 454 included patients," researchers said.

View Full Article in:

DoctorsLounge.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR